Fig. 2: Identification of EC response modifiers to bevacizumab.
From: Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy
a Workflow of the 3D kinome-wide CRISPR screen. b Viable cell number determined before screening selection. Error bars represent ± SEM (n = 2 independent experiments). c Cell survival during screening selection. Surviving EC fraction is the ratio of relative viable cell number on a specific day versus that on day 0. Curves represent results from one experiment. d, e Identification of candidate genes. Candidate genes were identified using the α-RRA score (shown as –log10 α-RRA score) on day 12 (d) or 21 (e). Blue or red dots represent candidate genes (FDR ≤ 0.3) identified from positive or negative selection (bevacizumab versus palivizumab), respectively. Small gray dots represent the neutral genes. Results represent two independent experiments (n = 2).
